Lung Diseases  >>  albuterol inhalational powder (A006 DPI)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
albuterol inhalational powder (A006 DPI) / Amphastar
NCT01174732: Dose-Ranging Study of A006 DPI, in Adult Asthma Patients

Completed
2
26
US
albuterol inhalation powder, Placebo, albuterol inhalation aerosol, Proventil
Amphastar Pharmaceuticals, Inc.
Asthma, Bronchospasm
10/10
01/11
NCT01189396: Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006

Completed
2
27
US
A006, Placebo DPI, Proventil-HFA
Amphastar Pharmaceuticals, Inc.
Asthma, Bronchospasm, Chronic Obstructive Pulmonary Disease (COPD)
12/10
01/11
NCT01581177: Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation

Completed
2
23
US
Albuterol DPI 25 mcg/inh, Albuterol DPI 90 mcg/inh, Placebo DPI, Albuterol MDI 90 mcg/inh
Amphastar Pharmaceuticals, Inc.
Asthma
07/12
08/12
NCT02210806: Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation

Completed
2
22
US
A006 DPI, Albuterol, Albuterol DPI, Placebo DPI, Placebo, Proventil® MDI, Proventil®
Amphastar Pharmaceuticals, Inc.
Asthma
09/14
10/14

Download Options